Oppenheimer lowered the firm’s price target on Viking Therapeutics (VKTX) to $100 from $164 and keeps an Outperform rating on the shares. Despite impressive clinical progress for VK2735 subQ and oral facing promising obesity opportunities, Viking has underperformed, the firm notes. Investors have seen obesity deal dynamics as negative read-across to Viking. Oppenheimer’s analysis suggests Viking could sign a deal if they choose or also could advance to market independently.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- VKTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Buy Rating for Viking Therapeutics Driven by Promising VK2735 Oral GLP-1 Agonist Potential
- H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data
- Eli Lilly jumps as results from weight-loss pill study rival competitor’s
- JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics